NSCLC represents the leading cause of cancer death throughout the developed world, but the introduction of a novel class of targeted anti-neoplastic agents, EGFR and ALK TKI directed against EGFR and ALK, has significantly changed the therapeutic options available for patients with NSCLC. The gene discussed is EGFR; the disease is cancer.